Acrocallosal Syndrome

Acrocallosal syndrome (ACLS) is a very rare genetic condition. It mainly affects the brain and the hands and feet. The key brain change is that the corpus callosum—the bridge that connects the right and left halves of the brain—does not form fully or is missing. Doctors call this “agenesis of the corpus callosum.” Many babies with this condition are also born with extra fingers or toes (polydactyly). Some have webbed or fused fingers or toes (syndactyly). Typical facial features can include widely spaced eyes and a prominent, high forehead. The head may be larger than average (macrocephaly). Problems are present at birth, but how severe they are can vary a lot from child to child. Most children have developmental delay and intellectual disability. Some have seizures. MedlinePlus

This condition is caused by changes (mutations) in genes that guide early body and brain development. The most common gene is KIF7. Less often, changes in GLI3 can lead to a similar picture. These genes are part of the Sonic Hedgehog pathway. This pathway helps cells know where to go and what to become in the growing embryo, especially in the brain and the limbs. When the pathway does not work well, the brain bridge may not form and extra digits may develop. MedlinePlus

ACLS is very rare. Only dozens of cases have been reported in medical journals. MedlinePlus

Other names

Doctors and resources may also use these names:

• Schinzel acrocallosal syndrome

• Schinzel syndrome 1

• ACLS or ACS

• Hallux duplication, postaxial polydactyly, and absence of corpus callosum (a descriptive label) MedlinePlusGenetic Rare Diseases Center

Types

Because this condition can look different from person to person, it helps to think of “types” by cause and by features:

1) By gene (cause):

• KIF7-related ACLS (autosomal recessive). A child gets one non-working KIF7 copy from each parent. Parents are usually healthy carriers. This is the classic form. MedlinePlusGenetic Rare Diseases Center

• GLI3-related ACLS (autosomal dominant). A single new (de novo) change in GLI3 can sometimes produce a severe form that overlaps with Greig cephalopolysyndactyly syndrome. Some experts consider GLI3-positive cases a severe end of Greig syndrome rather than “classic” ACLS. MedlinePlus

2) By brain findings:

• Complete agenesis of the corpus callosum. The bridge is absent.

• Partial agenesis/hypogenesis. The bridge is thin or partly formed. (These patterns are seen on MRI in reported cases.) MedlinePlus

3) By limb findings:

• Preaxial polydactyly. Extra thumb or big toe.

• Postaxial polydactyly. Extra little finger or little toe.

• With or without syndactyly. Fused or webbed digits may also be present. MedlinePlus

4) By overall severity:

• Milder neurodevelopmental impairment vs moderate-to-severe impairment, sometimes with seizures and more structural brain differences. Variation relates to which gene is changed, the exact variant, and—possibly—additional “modifier” genes. Research suggests ACLS belongs to the ciliopathy family (conditions where tiny cell structures called primary cilia do not work properly), and oligogenic effects (more than one gene contributing) may shape how the condition looks. PubMedNature

Causes

Important note: For ACLS, the primary cause is genetic. The items below explain the main gene causes and the different ways those gene changes can appear and act. They also include known pathway and inheritance mechanisms that “cause” the features we see.

1. Pathogenic variants in KIF7. This is the main, proven cause of classic ACLS. KIF7 helps cilia control the Sonic Hedgehog signal in early development. MedlinePlus

2. Truncating KIF7 variants (nonsense or frameshift). These create short, non-working KIF7 protein. MedlinePlus

3. Missense KIF7 variants in important domains. A single amino-acid change can disrupt KIF7 function enough to cause ACLS. MedlinePlus

4. Compound heterozygous KIF7 variants. Two different harmful KIF7 changes, one from each parent, can combine to cause disease. MedlinePlus

5. Homozygous KIF7 variants. The same variant is inherited from both carrier parents. MedlinePlus

6. GLI3 variants producing an ACLS-like picture. These are usually dominant and often de novo. They can mimic or be considered a severe form of Greig syndrome. MedlinePlus

7. Disrupted Sonic Hedgehog signaling. KIF7 and GLI3 act in this pathway. When signaling is too weak or mis-timed, brain and limb patterning is abnormal. MedlinePlus

8. Primary cilia dysfunction (a ciliopathy mechanism). KIF7 helps cilia “sense” hedgehog signals. Faulty cilia lead to mis-patterning across the embryo. PubMed

9. Oligogenic influences. Rare variants in other cilia genes (e.g., AHI1, BBS2, BBS4) may modify severity in some families. PubMed

10. De novo dominant GLI3 mutation. A new, not-inherited change can cause ACLS-like features even when parents are unaffected. MedlinePlus

11. Autosomal recessive inheritance (KIF7). Needing two altered copies explains why unaffected parents can have an affected child. MedlinePlusGenetic Rare Diseases Center

12. Consanguinity increases risk for recessive KIF7 disease because both parents may carry the same rare variant. (Reported in case series.) MedlinePlus

13. Loss of GLI3 repressor/activator balance. GLI3 must be precisely processed. Changes shift the activator/repressor balance, disturbing limb and brain patterning. MedlinePlus

14. KIF7 variants affecting microtubule motor function. KIF7 is a kinesin; motor defects impair ciliary signal traffic. PubMed

15. Hedgehog gradient mis-reading. Cells misinterpret positional cues, leading to extra digits and midline brain anomalies. MedlinePlus

16. Reduced axon guidance across the midline. Without proper signaling, callosal axons fail to cross, leaving the corpus callosum thin or absent. (Consistent with ACC biology.) MedlinePlus

17. Abnormal cerebral cortical development. Some children have brain cysts or cortical changes that follow from early patterning errors. MedlinePlus

18. Modifier genes outside cilia network. Research hints that additional variants can alter severity, helping explain family-to-family differences. PubMed

19. Dominant-negative GLI3 effects. Certain GLI3 changes may interfere with normal protein, amplifying impact from one altered copy. MedlinePlus

20. Gene-negative ACLS-like cases (rare). A few reported patients have a classic picture but no mutation found yet, likely due to undiscovered genes in the same pathway. (This reflects rarity and limits of testing.) MedlinePlus

Symptoms and signs

1. Developmental delay. Slow to reach milestones such as sitting, walking, and talking because the brain bridge and other areas did not form typically. MedlinePlus

2. Intellectual disability. Learning and problem-solving are harder; support is needed at home and school. MedlinePlus

3. Low muscle tone (hypotonia). Babies may feel “floppy,” which delays motor skills and balance.

4. Seizures. Some children have convulsions or brief staring spells that need EEG testing and medicine. MedlinePlus

5. Macrocephaly. Head size is larger than average. Doctors measure this over time. MedlinePlus

6. Agenesis or hypogenesis of the corpus callosum. This is the core brain feature and is seen on MRI. It affects how brain halves share information. MedlinePlus

7. Polydactyly (extra fingers/toes). May be near the thumb/big toe (preaxial) or near the little finger/toe (postaxial). Sometimes both. MedlinePlus

8. Syndactyly (webbing/fusion). Adjacent digits may be joined by skin or soft tissue. MedlinePlus

9. Widely spaced eyes (hypertelorism). This is a common facial feature. MedlinePlus

10. Prominent, high forehead. Forehead shape stands out and helps doctors recognize the pattern. MedlinePlus

11. Feeding difficulties in infancy. Low tone and coordination problems can make feeding slow at first.

12. Speech delay. Speech often comes later and may need therapy.

13. Behavioral challenges. Frustration, attention difficulty, or sensory issues can occur due to developmental differences.

14. Coordination and balance problems. Some children are clumsy or have unsteady gait because of brain wiring differences.

15. Possible brain cysts or other brain structure differences. These can add to symptoms depending on size and location. MedlinePlus

Diagnostic tests

Goal: confirm the diagnosis, understand the child’s needs, and guide care. Tests span the exam room, lab, electrical studies, and imaging.

A) Physical examination

1. General pediatric exam. The doctor checks weight, length/height, head size, and overall health. Head size and growth curve help track macrocephaly and nutrition.

2. Detailed dysmorphology exam. A clinical geneticist looks for facial features (wide-set eyes, high forehead), limb differences (extra or fused digits), and other birth defects that fit ACLS. MedlinePlus

3. Neurological exam. Muscle tone, reflexes, strength, and coordination are checked to understand motor delay and guide therapy.

4. Developmental assessment in clinic. Simple age-based screenings (like milestone checklists) help decide if formal testing is needed.

5. Family history and three-generation pedigree. This helps see inheritance patterns and consider carrier testing.

B) Manual / bedside developmental tests

6. Standardized developmental testing (e.g., Bayley Scales or similar tools available locally). These give a clear picture of motor, language, and cognitive skills to plan therapy.

7. Adaptive behavior interview (e.g., Vineland-type tools). Parents describe daily living skills, which guides school supports.

8. Speech-language evaluation. A speech therapist checks understanding, expression, and oral-motor coordination to plan therapy.

9. Physical and occupational therapy evaluations. Therapists test posture, balance, hand use, and daily skills to design exercises and supports.

10. Vision and hearing screening. Simple bedside checks decide if formal audiology or eye exams are needed, since sensory issues can worsen learning problems.

C) Laboratory and pathological/genetic tests

11. Chromosomal microarray (CMA). First-line genetic test to look for extra or missing DNA segments that might contribute to the picture when diagnosis is uncertain.

12. Single-gene testing for KIF7. Looks for harmful changes in KIF7; the commonest proven cause of classic ACLS. MedlinePlus

13. GLI3 analysis. If features overlap with Greig syndrome or if the pattern suggests a dominant/de novo change, GLI3 sequencing is helpful. MedlinePlus

14. Multigene panel for ciliopathies/hedgehog pathway. A panel can check KIF7, GLI3, and related cilia genes at once. Panels can also detect some deletions/duplications. Research shows ACLS sits within the ciliopathy group. PubMedNature

15. Trio-based exome or genome sequencing. Testing the child and both parents can find rare or new variants and clarify inheritance when single-gene tests are negative.

D) Electrodiagnostic tests

16. EEG (electroencephalogram). Checks brain electrical activity if seizures or staring spells are suspected. Helps choose anti-seizure medicine. MedlinePlus

17. Auditory brainstem response (ABR). If hearing concerns arise, ABR measures how sound travels along the hearing nerve to the brainstem.

18. Visual evoked potentials (VEP). If vision concerns or unusual eye movements are present, VEP measures how the brain responds to visual signals.

E) Imaging tests

19. Brain MRI (preferred). Shows whether the corpus callosum is absent or thin, and looks for brain cysts or other structural changes that explain symptoms. This is the key imaging study. MedlinePlus

20. Fetal MRI (during pregnancy, when indicated). If ultrasound suggests callosal agenesis or extra digits, fetal MRI can give more detail for planning.

21. Prenatal ultrasound. Can detect polydactyly and sometimes callosal anomalies in late second or third trimester.

22. Postnatal cranial ultrasound (for newborns, when the fontanelle is open). A quick, bedside way to screen for major brain changes before MRI.

23. Skeletal X-rays of hands and feet. Confirms number and structure of extra digits and the presence of any bone fusion.

24. Spine or limb imaging as needed. Checks for other bone differences that might affect walking or hand function.

25. Echocardiogram and renal ultrasound (case-by-case). Some children with complex genetic syndromes may have heart or kidney differences; doctors screen based on findings and family history (individualized).

26. Follow-up MRIs. Done if seizures, new symptoms, or developmental changes appear and more detail is needed for care.

Non-pharmacological treatments

(15 physiotherapy/rehabilitation approaches + mind-body supports + gene/education-focused care)
Each item includes a short description, purpose, mechanism, and benefits.

A) Physiotherapy / rehabilitation approaches

1. Early developmental physiotherapy
   Description: Play-based movement sessions from infancy.
   Purpose: Build motor milestones—head control, rolling, sitting, crawling.
   Mechanism: Repeated, graded practice strengthens neural pathways and muscles.
   Benefits: Faster milestone gains; better posture and balance.

2. Neurodevelopmental treatment (NDT/Bobath)
   Description: Hands-on facilitation to guide better movement patterns.
   Purpose: Reduce abnormal tone and promote efficient movement.
   Mechanism: External cues reshape motor programs through sensory feedback.
   Benefits: Smoother transitions (sit-to-stand), improved trunk control.

3. Task-specific training
   Description: Practice the exact activity (e.g., reaching, grasping, walking).
   Purpose: Improve real-life function.
   Mechanism: Motor learning is task-dependent and strengthens used circuits.
   Benefits: Better self-care and play skills.

4. Strength training (age-appropriate)
   Description: Light resistance play, sit-to-stand repeats, step-ups.
   Purpose: Increase muscle strength and endurance.
   Mechanism: Progressive overload in safe ranges.
   Benefits: More stamina for daily activities; fewer falls.

5. Stretching and range-of-motion (ROM)
   Description: Gentle daily stretches and joint mobilization.
   Purpose: Prevent contractures in ankles, knees, wrists.
   Mechanism: Maintains muscle-tendon length and joint glide.
   Benefits: Easier walking, dressing, and positioning.

6. Balance and vestibular training
   Description: Standing on foam, stepping stones, balance boards.
   Purpose: Improve postural control and reduce falls.
   Mechanism: Challenges sensory integration for balance.
   Benefits: Safer mobility; more confidence.

7. Gait training (with or without walker/orthoses)
   Description: Treadmill or over-ground guided walking.
   Purpose: Develop efficient gait and endurance.
   Mechanism: Rhythmic step training entrains central pattern generators.
   Benefits: Longer walking distances; better community mobility.

8. Orthotics and adaptive equipment
   Description: AFOs, wrist splints, supportive seating, standers.
   Purpose: Align joints and support weak muscles.
   Mechanism: External stabilization improves biomechanics.
   Benefits: Less fatigue; better hand use and standing tolerance.

9. Constraint-induced movement therapy (CIMT)
   Description: Temporarily limit the stronger hand to train the weaker one.
   Purpose: Improve function of the less-used upper limb.
   Mechanism: Forced use drives cortical reorganization.
   Benefits: Better grasp, release, and bimanual tasks.

10. Sensory integration therapy (OT-led)
    Description: Controlled sensory play (brushing, swings, textures).
    Purpose: Calm sensory over- or under-responsivity.
    Mechanism: Graded sensory input normalizes processing.
    Benefits: Improved attention, feeding, and sleep.

11. Fine-motor and hand-function therapy (OT)
    Description: Grasp patterns, in-hand manipulation, tool use.
    Purpose: Build hand skills for self-care and school.
    Mechanism: Repetition strengthens finger-specific motor maps.
    Benefits: Better feeding, writing, and play.

12. Speech-language therapy (SLT)
    Description: Early communication supports, AAC if needed.
    Purpose: Improve speech, language, and social communication.
    Mechanism: Modeling + high-frequency practice + assistive tech.
    Benefits: Clearer expression; fewer behavior frustrations.

13. Feeding and oral-motor therapy
    Description: Positioning, texture progression, swallow safety.
    Purpose: Reduce choking and improve nutrition.
    Mechanism: Oral-motor patterning and sensory desensitization.
    Benefits: Safer feeds; weight gain; less reflux.

14. Respiratory and postural care
    Description: Positioning, chest physiotherapy when needed.
    Purpose: Support breathing and reduce infections.
    Mechanism: Better ventilation and secretion clearance.
    Benefits: Fewer hospital visits; more energy.

15. Hydrotherapy or hippotherapy (where available)
    Description: Water-based therapy or therapist-guided horseback movement.
    Purpose: Enhance trunk control, balance, and sensory input.
    Mechanism: Buoyancy/responsive movement challenges core control.
    Benefits: Fun sessions; improved balance and engagement.

B) Mind-body and family supports

16. Caregiver coaching and home programs
    Description: Teach parents daily exercises and communication strategies.
    Purpose: Carry therapy gains into real life.
    Mechanism: High-dose, meaningful practice at home.
    Benefits: Faster progress and family confidence.

17. Structured routines and visual schedules
    Description: Picture boards, timers, predictable sequences.
    Purpose: Reduce anxiety and improve behavior.
    Mechanism: External structure supports executive function.
    Benefits: Smoother mornings, mealtimes, and therapy sessions.

18. Behavior therapy (including ABC strategies)
    Description: Track triggers, teach alternative skills, reward success.
    Purpose: Manage outbursts, improve cooperation.
    Mechanism: Positive reinforcement and skill replacement.
    Benefits: Safer home and better learning.

19. Mindfulness/play-based calming for child & caregiver
    Description: Short breathing games, music, story yoga.
    Purpose: Lower stress and improve attention.
    Mechanism: Parasympathetic activation and self-regulation practice.
    Benefits: Better sleep and therapy participation.

20. Peer-supported inclusive play/schooling
    Description: Inclusion with supports, buddy systems.
    Purpose: Build social skills and language.
    Mechanism: Naturalistic modeling in groups.
    Benefits: Confidence and friendships.

C) Gene/education-focused care

21. Genetic counseling
    Description: Explain inheritance, testing options, and recurrence risk.
    Purpose: Help families plan future pregnancies.
    Mechanism: Risk assessment based on family and molecular results.
    Benefits: Informed choices; access to support networks.

22. Early intervention (EI) services
    Description: State/community programs from 0–3 years.
    Purpose: Use the brain’s highest plasticity window.
    Mechanism: Frequent, team-based therapy.
    Benefits: Best chance for strong early gains.

23. Individualized Education Plan (IEP)
    Description: School-based supports, accommodations, AAC, PT/OT/SLT.
    Purpose: Ensure access to learning.
    Mechanism: Legal framework for services and goals.
    Benefits: Steady progress in school skills.

24. Transition planning (adolescence onward)
    Description: Life-skills training, vocation, community mobility.
    Purpose: Promote independence and participation.
    Mechanism: Goal-based coaching and assistive technology.
    Benefits: Better adult outcomes and dignity.

25. Clinical trial awareness (research registry)
    Description: Learn about studies for corpus callosum disorders.
    Purpose: Consider safe research participation.
    Mechanism: IRB-approved protocols with monitoring.
    Benefits: Access to cutting-edge assessments; advances knowledge.

Note: There is no established gene therapy for ACS today. Any gene-targeted approach is research-only and should be considered inside regulated clinical trials.

---

Drug treatments

There is no single “ACS drug.” Doses below are typical pediatric ranges and must be individualized by your child’s clinician based on age, weight, and comorbidities.

1. Levetiracetam (antiepileptic)
   Dose/time: ~10–60 mg/kg/day in 2 doses.
   Purpose: Control seizures.
   Mechanism: Modulates synaptic vesicle protein SV2A to reduce neuronal excitability.
   Side effects: Irritability, sleep changes; rarely mood swings.

2. Valproate / Sodium valproate (antiepileptic)
   Dose/time: ~10–60 mg/kg/day in divided doses; monitor levels.
   Purpose: Broad-spectrum seizure control.
   Mechanism: Increases GABA; blocks sodium/calcium channels.
   Side effects: Weight gain, tremor, liver toxicity, thrombocytopenia; avoid in pregnancy.

3. Clobazam (benzodiazepine adjunct)
   Dose/time: ~0.25–1 mg/kg/day in 1–2 doses.
   Purpose: Add-on for difficult seizures.
   Mechanism: Enhances GABA-A inhibition.
   Side effects: Sedation, drooling, tolerance.

4. Topiramate (antiepileptic)
   Dose/time: ~1–9 mg/kg/day divided BID.
   Purpose: Seizures and sometimes migraine.
   Mechanism: Blocks sodium channels; enhances GABA; inhibits AMPA.
   Side effects: Appetite loss, tingling, word-finding issues, kidney stones.

5. Lamotrigine (antiepileptic)
   Dose/time: Slow titration to ~1–5 mg/kg/day; avoid rapid changes.
   Purpose: Focal/generalized seizures.
   Mechanism: Stabilizes neuronal membranes by sodium-channel block.
   Side effects: Rash (SJS risk) if titrated too fast, dizziness.

6. Baclofen (antispasticity)
   Dose/time: Oral ~0.3–2 mg/kg/day in 3–4 doses; intrathecal pump in select cases.
   Purpose: Reduce spasticity and painful spasms.
   Mechanism: GABA-B agonist reduces spinal reflexes.
   Side effects: Drowsiness, weakness, constipation; withdrawal if stopped abruptly.

7. Tizanidine (antispasticity)
   Dose/time: Start low; titrate (clinician-guided).
   Purpose: Alternative or add-on to baclofen.
   Mechanism: Alpha-2 agonist reduces excitatory neurotransmission.
   Side effects: Sedation, low blood pressure, dry mouth.

8. Botulinum toxin type A (focal tone management)
   Dose/time: Weight/ muscle-based injections every 3–6 months.
   Purpose: Relax overactive muscles to improve ROM and function.
   Mechanism: Blocks acetylcholine release at neuromuscular junction.
   Side effects: Local weakness, pain at injection site.

9. Melatonin (sleep regulation)
   Dose/time: ~1–5 mg 30–60 min before bedtime (child-specific).
   Purpose: Improve sleep onset and quality.
   Mechanism: Aligns circadian rhythm.
   Side effects: Morning grogginess, vivid dreams.

10. Proton-pump inhibitor (e.g., omeprazole) for reflux
    Dose/time: ~0.7–3.5 mg/kg/day once daily.
    Purpose: Reduce gastroesophageal reflux symptoms.
    Mechanism: Blocks gastric acid secretion.
    Side effects: Diarrhea, abdominal pain; long-term: nutrient issues.

11. H2 blocker (e.g., ranitidine alternatives/ famotidine)
    Dose/time: Clinician-guided pediatric dosing.
    Purpose: Reflux if PPI not tolerated.
    Mechanism: Histamine-2 receptor block reduces acid.
    Side effects: Headache, constipation/diarrhea.

12. Polyethylene glycol (PEG) for constipation
    Dose/time: ~0.4–1 g/kg/day; adjust to effect.
    Purpose: Soften stools and ease bowel movements.
    Mechanism: Osmotic water retention in stool.
    Side effects: Bloating, cramps.

13. Vitamin D (if deficient)
    Dose/time: Typically 600–1000 IU/day; higher repletion per labs.
    Purpose: Bone health, muscle function.
    Mechanism: Supports calcium absorption and neuromuscular function.
    Side effects: Rare with standard dosing.

14. Iron (if iron-deficiency present)
    Dose/time: ~3–6 mg/kg/day elemental iron divided.
    Purpose: Treat anemia and support cognition.
    Mechanism: Replaces iron stores for hemoglobin and brain enzymes.
    Side effects: Constipation, dark stools, nausea.

15. Broad-spectrum antibiotics (only when infection is diagnosed)
    Dose/time: Drug- and infection-specific (physician-directed).
    Purpose: Treat ear, chest, or urinary infections.
    Mechanism: Kill or stop bacteria growth.
    Side effects: Diarrhea, allergy; use only when needed.

Safety notes:
• Epilepsy drugs require careful selection and monitoring.
• Tone medicines can worsen weakness—dosing and goals must be clear.
• Supplements and reflux medicines should follow lab results and growth tracking.
• Always discuss pregnancy risks and interactions with your clinician.

---

Dietary molecular supplements

1. Omega-3 (DHA/EPA) – ~250–500 mg/day combined (child dose varies by weight).
   Function: Supports brain cell membranes. Mechanism: Anti-inflammatory lipid mediators.

2. Vitamin D3 – 600–1000 IU/day (or per labs).
   Function: Bone, muscle, immune support. Mechanism: Nuclear receptor signaling.

3. Iron (if low) – ~3–6 mg/kg/day elemental iron.
   Function: Oxygen delivery and myelination enzymes. Mechanism: Replenishes stores.

4. Vitamin B12 – 1–5 µg/day (or per deficiency plan).
   Function: Myelin and DNA synthesis. Mechanism: Cofactor for methylation.

5. Folate (B9) – 200–400 µg/day (diet/ supplement per labs).
   Function: Neural development and RBCs. Mechanism: One-carbon metabolism.

6. Choline – ~125–500 mg/day (age-based).
   Function: Acetylcholine and membrane phospholipids. Mechanism: Neurotransmitter precursor.

7. Coenzyme Q10 – ~2–5 mg/kg/day.
   Function: Mitochondrial energy support. Mechanism: Electron transport chain cofactor.

8. Magnesium – diet-first; supplement only if low.
   Function: Neuromuscular stability. Mechanism: NMDA modulation, enzyme cofactor.

9. Zinc – diet-first; supplement per labs.
   Function: Growth and immune enzymes. Mechanism: Enzymatic cofactor.

10. Probiotics – strain-specific, clinician-guided.
    Function: Gut health, stool regularity. Mechanism: Microbiome modulation.

Evidence for “brain improvement” from supplements in ACS is limited. Use supplements to correct deficiencies, not as substitutes for therapy.

---

Regenerative / stem-cell drugs

Important caution: There are no approved “immunity booster” or stem-cell drugs for ACS. The items below are research-context only or situation-specific; no routine dosing is recommended outside specialist care or clinical trials.

1. Hematopoietic or mesenchymal stem-cell therapy (experimental)
   Function/mechanism: Attempted neural support or anti-inflammatory effects. Status: Research only; not proven for ACS.

2. Gene-targeted therapy concepts (KIF7/GLI-pathway)
   Function/mechanism: Aim to correct or bypass mutated signaling. Status: Preclinical/early research; no clinical dosing.

3. IGF-1 or growth-hormone therapy (only if true deficiency)
   Function/mechanism: Supports growth and possibly myelination. Status: Use only when lab-confirmed deficiency exists; specialist dosing.

4. Erythropoietin derivatives (neuroprotective research)
   Function/mechanism: Experimental neurotrophic effects. Status: Not indicated for ACS outside trials.

5. N-acetylcysteine (NAC) neuroprotection research
   Function/mechanism: Antioxidant/glutathione support in some neuro disorders. Status: Off-label only with specialist oversight.

6. Mitochondrial cocktails (e.g., riboflavin, CoQ10) in proven mitochondrial overlap
   Function/mechanism: Support energy pathways if mitochondrial disease is confirmed. Status: Case-by-case; clinician-directed.

Please avoid clinics advertising “stem-cell cures.” Seek board-certified specialists and registered clinical trials only.

---

Surgeries

1. Excision of extra digits (polydactyly surgery)
   Procedure: Remove extra finger/toe; reconstruct soft tissue/tendon.
   Why: Improve function, fit of shoes/gloves, and appearance.

2. Craniofacial surgery (if indicated)
   Procedure: Correct craniosynostosis or facial asymmetry when present.
   Why: Protect brain growth, relieve pressure, and improve airway/feeding.

3. Hydrocephalus diversion (VP shunt/endoscopic third ventriculostomy)
   Procedure: Divert CSF to relieve pressure.
   Why: Prevent headaches, vomiting, vision problems, and developmental setback.

4. Cleft palate repair / airway procedures (if present)
   Procedure: Close palate; address airway obstruction.
   Why: Improve feeding, speech, and breathing safety.

5. Strabismus surgery (eye muscle alignment)
   Procedure: Adjust eye muscles to align gaze.
   Why: Support binocular vision and reduce amblyopia risk.

---

Preventions and proactive steps

1. Genetic counseling before future pregnancies.

2. Molecular testing of the affected child to define the exact variant.

3. Carrier testing for parents when a pathogenic variant is found.

4. Prenatal options (CVS/amniocentesis) or preimplantation genetic testing in future pregnancies.

5. Folic acid for all women planning pregnancy (at least 400 µg/day; higher if advised).

6. Avoid alcohol, tobacco, and non-prescribed drugs during pregnancy.

7. Manage maternal conditions (diabetes, thyroid disease, infections).

8. Vaccinations up to date for mother and infant to reduce serious infections.

9. Early referral to EI/therapy at diagnosis to catch the neuroplastic window.

10. Home safety planning (seizure plan, aspiration prevention, car seat/positioning).

---

When to see doctors urgently or soon

• New or worsening seizures, staring spells, or unusual stiffening.

• Poor feeding, choking, reflux with weight loss, or dehydration.

• Breathing trouble, frequent chest infections, persistent cough.

• Vomiting with headache, sudden sleepiness, or bulging fontanelle (possible pressure).

• Fever in infants, or illness not improving.

• Developmental regression—loss of skills already learned.

• Severe constipation, pain, or no stool for several days despite home care.

• Any caregiver concern that “something is not right.”

---

What to eat and what to avoid

What to eat:

• Balanced meals with fruits, vegetables, whole grains, legumes.

• Adequate protein (eggs, fish, lean meats, dairy, tofu, lentils) for muscle rebuilding.

• Healthy fats (olive oil, nuts, seeds, oily fish) to support brain structure.

• Fiber and fluids to prevent constipation (oats, pears, prunes, water).

• Calcium and vitamin D sources for bones (milk/yogurt or fortified alternatives).

What to avoid or limit:

• Choking-risk textures if oral-motor problems (nuts, hard candies) unless cleared by therapist—use safe forms.

• Excess added sugars and ultra-processed snacks that crowd out nutrients.

• Very acidic/spicy foods if reflux is a problem.

• Unverified “miracle cures” or high-dose supplements without medical advice.

---

Frequently Asked Questions (FAQs)

1. Is ACS caused by something I did during pregnancy?
   No. ACS is genetic. It happens very early in development because of changes in growth-guiding genes.

2. Is there a cure?
   There is no single cure yet. Care focuses on therapies, symptom control, nutrition, and surgeries when needed.

3. Will my child walk or talk?
   Many children make meaningful gains with early therapy. Abilities vary. Intensive, family-centered programs help.

4. Are seizures common?
   Seizures can occur and are treatable. Regular follow-up with a pediatric neurologist is important.

5. What is the outlook?
   Outcomes differ widely. Early intervention, consistent home programs, and treating medical issues improve quality of life.

6. Can we prevent ACS in the next pregnancy?
   You cannot “prevent” the gene variant, but genetic counseling, carrier testing, and prenatal/embryo testing can inform choices.

7. Is gene therapy available now?
   Not at this time for ACS. Research is ongoing. Consider registered clinical trials if appropriate.

8. Will diet change the brain malformation?
   Diet cannot change brain structure, but good nutrition supports growth, energy, and therapy participation.

9. Do supplements help?
   Supplements help mainly when there is a proven deficiency. Avoid high-dose or multi-supplement plans without labs.

10. What specialists should we see?
    Pediatric neurologist, geneticist, developmental pediatrician, PT/OT/SLT, ophthalmology, orthopedics/hand, nutrition, and sometimes neurosurgery/ENT.

11. How often should therapies happen?
    Higher frequency in early years is best. Your team will set a plan based on goals and tolerance.

12. What about school?
    Ask for an IEP with accommodations, therapy services, and assistive communication if needed.

13. Is behavior therapy helpful?
    Yes. Positive behavior supports and structured routines reduce stress and improve learning.

14. Are stem-cell clinics safe?
    Be very cautious. For ACS, stem-cell treatments are not proven. Use only regulated clinical trials.

15. How can we care for ourselves as caregivers?
    Accept help, keep medical records organized, join support groups, and schedule breaks. A supported caregiver helps the child thrive.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 02, 2025.